Carryover and the ghost peak from last week's standard — what changed since posts 61–90
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Post #60 answers the question as asked. The question underneath it is different.
A chromatogram image at a resolution where you can see peak shape but not baseline detail is worth having and is not the same as the data. Ask for the integration table if the number matters.
Noting that the question and the thing people usually mean by it are different.
Collapsed as off-topic by two members at trust level 3 or above
The honest answer on Carryover is that it depends, and the useful part is the list of what it depends on. Four items, in rough order of how much they matter.
Most people get the first two right and then argue about the fourth.
I read the earlier replies on Carryover twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what was said rather than what I expected.
Everything in post #62 holds. The case it does not cover is the one I have.
This is why a purity figure without the underlying chromatogram is weaker evidence than it appears. It is also why two competent laboratories can report different numbers on the same vial without either being wrong.
Not a strong opinion, just a consistent one.
Injection volume matters because column overload distorts peak shape, and an overloaded main peak can swallow a small neighbour. A certificate without injection volume is missing something load-bearing.
Carryover is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.
Change the wavelength and the proportions change even though the sample has not. That is the reason the wavelength has to be on the document for the number to mean anything.
I had written a reply contradicting post #70 and deleted it. Here is what survived.
One caution on Carryover: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.
A shoulder on the trailing edge is most often a closely related species rather than an artefact. The way to find out is to change the gradient slope, not to argue about the integration.
Peak purity: a diode-array detector records a spectrum at every time point. If a peak contains two co-eluting species with different spectra, the spectrum changes across the peak. A passing peak-purity result says the spectrum is constant; it is weak evidence of homogeneity if the impurities have similar spectra.
Before anything else: what was the gradient, and at what wavelength? Area percent at different wavelengths is not the same number even on the same sample because different species absorb differently at different wavelengths. With the method stated, I can tell you something useful. Without it, all I can say is that there is one large peak.
Written from notes rather than memory, which is why the numbers are specific.
Collapsed as off-topic by two members at trust level 3 or above
Coming back to post #74, because the follow-up matters more than the original answer.
Method validation is the demonstration that a method can separate the compound from its degradation products and impurities reliably. A method that cannot resolve an impurity from the parent peak will not detect that impurity.
A modest claim, modestly supported.
Agreed on all of that, and I have nothing to add to it.
I would be cautious about generalising from the Carryover example above. It is a good example. It is one example.
Typical suitability criteria are a replicate area relative standard deviation below about two per cent, a tailing factor inside a defined window, a resolution minimum against a specified peak, and a plate-count floor.
That is what the documentation says. What happens in practice is usually close.
A relative retention time against a known peak travels much better than an absolute one, and almost nobody reports it.
Marking that as an opinion rather than a finding.
Carryover is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.
Reversed-phase separates on hydrophobicity. A peptide is retained on a non-polar stationary phase and eluted by increasing organic solvent. For peptides the mobile phase almost always contains an ion-pairing acid, typically 0.1% TFA, which suppresses secondary interactions and sharpens peaks.
I would put a moderate confidence on that and no more.
Collapsed as off-topic by two members at trust level 3 or above
Peaks that do not elute do not appear in the area percentage. Aggregates and strongly retained species can be entirely invisible to a standard method, which is a ceiling on what any purity figure can claim.
Where I would look next, rather than where I would stop.
Post #88 describes the usual case. This is about the unusual one.
Column chemistry and particle size: smaller particles (1.7 μm) give better resolution and higher efficiency than larger particles (3.5 μm or 5 μm), at the cost of higher back pressure. Newer methods increasingly use smaller particles.
Careful with the language on Carryover. "Not detected" and "not present" are different findings and the first is a statement about the method.